EP3698798A4 - Hyperphosphatemia treatment agent, and particles - Google Patents

Hyperphosphatemia treatment agent, and particles Download PDF

Info

Publication number
EP3698798A4
EP3698798A4 EP18868309.8A EP18868309A EP3698798A4 EP 3698798 A4 EP3698798 A4 EP 3698798A4 EP 18868309 A EP18868309 A EP 18868309A EP 3698798 A4 EP3698798 A4 EP 3698798A4
Authority
EP
European Patent Office
Prior art keywords
particles
treatment agent
hyperphosphatemia
hyperphosphatemia treatment
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18868309.8A
Other languages
German (de)
French (fr)
Other versions
EP3698798A1 (en
Inventor
Shinsuke Tokuoka
Hayato Yoshida
Yuichiro Kondo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Kyowa Kirin Co Ltd
Original Assignee
Fujifilm Corp
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp, Kyowa Kirin Co Ltd filed Critical Fujifilm Corp
Publication of EP3698798A1 publication Critical patent/EP3698798A1/en
Publication of EP3698798A4 publication Critical patent/EP3698798A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
EP18868309.8A 2017-10-16 2018-10-16 Hyperphosphatemia treatment agent, and particles Pending EP3698798A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017200017 2017-10-16
JP2017252894 2017-12-28
JP2018121072 2018-06-26
PCT/JP2018/038466 WO2019078198A1 (en) 2017-10-16 2018-10-16 Hyperphosphatemia treatment agent, and particles

Publications (2)

Publication Number Publication Date
EP3698798A1 EP3698798A1 (en) 2020-08-26
EP3698798A4 true EP3698798A4 (en) 2020-12-23

Family

ID=66173379

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18868309.8A Pending EP3698798A4 (en) 2017-10-16 2018-10-16 Hyperphosphatemia treatment agent, and particles

Country Status (8)

Country Link
US (2) US20190321393A1 (en)
EP (1) EP3698798A4 (en)
JP (2) JP7018451B2 (en)
CN (1) CN111246857A (en)
AU (1) AU2018352766B2 (en)
CA (1) CA3079171C (en)
TW (1) TW201922268A (en)
WO (1) WO2019078198A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017145142A1 (en) 2016-02-25 2017-08-31 Nobio Ltd. Micro and nanoparticulate compositions comprising anti-microbially active groups
MX2019007904A (en) 2016-12-28 2019-09-09 Fujifilm Corp Emulsion of nitrogen atom-containing polymer or salt thereof, production method therefor, and production method for particles.
US11134676B2 (en) 2017-08-30 2021-10-05 Nobio Ltd. Anti-microbial particles and methods of use thereof
CN111225674A (en) 2017-10-16 2020-06-02 富士胶片株式会社 Therapeutic agent for hyperphosphatemia
AU2021208491A1 (en) * 2020-01-16 2022-08-18 Vifor Fresenius Medical Care Renal Pharma, Ltd. Particles of a mixture of iron(III)-oxyhydroxide, sucrose and one or more starches, preferably of sucroferric oxyhydroxide
CN113679616B (en) * 2021-08-24 2023-04-18 浙江大学 Cationic polymer-based dental adhesion pretreatment agent and application method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0143328A2 (en) * 1983-10-25 1985-06-05 Nitto Boseki Co., Ltd. Small-flobular crosslinked monoallylamine polymer and process for producing the same
US20050147580A1 (en) * 2003-11-03 2005-07-07 Eric Connor Anion-binding polymers and uses thereof
EP2481414A1 (en) * 2011-02-01 2012-08-01 Chemi SPA A process for the preparation of cross-linked polyallylamines or pharmaceutically acceptable salts thereof
EP3564292A1 (en) * 2016-12-28 2019-11-06 Fujifilm Corporation Emulsion of nitrogen atom-containing polymer or salt thereof, production method therefor, and production method for particles

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496545A (en) * 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
TR199902794T2 (en) * 1997-02-19 2000-04-21 The Procter & Gamble Company Ion, interchangeable hydrogel-forming polymer compositions in a mixed layer and absorbent elements containing these compositions in relatively high concentrations.
TW592727B (en) * 1997-04-04 2004-06-21 Chugai Pharmaceutical Co Ltd Phosphate-binding polymer preparations
JP3389493B2 (en) 1997-04-04 2003-03-24 中外製薬株式会社 Phosphate-binding polymer preparation
JP3952223B2 (en) 1997-05-28 2007-08-01 日東紡績株式会社 Allylamine polymer
TW568788B (en) 1998-10-12 2004-01-01 Chugai Pharmaceutical Co Ltd Polymer combining with phosphoric acid and preparation containing the same
US6180754B1 (en) 1999-09-03 2001-01-30 The Dow Chemical Company Process for producing cross-linked polyallylamine polymer
AU2001241077A1 (en) * 2000-03-09 2001-09-17 Hisamitsu Pharmaceutical Co. Inc. Crosslinked anion-exchange resin or salt thereof and phosphorus adsorbent comprising the same
MXPA03009572A (en) 2001-04-18 2004-02-12 Genzyme Corp Low salt forms of polyallylamine.
US7459502B2 (en) 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
ES2342947T3 (en) * 2004-10-13 2010-07-19 Ilypsa, Inc. RECYCLED AMINA POLYMERS.
JP2008527068A (en) * 2004-12-30 2008-07-24 ハダシット メディカル リサーチ サーヴィシーズ アンド ディヴェロップメント リミテッド Antibacterial nanoparticle additives forming non-leaching persistent antibacterial polymer compounds
CA2601236A1 (en) 2005-03-16 2006-09-21 Usv Limited An improved process for the preparation of crosslinked polyallylamine polymer
CA2749074A1 (en) 2006-09-01 2008-05-29 Usv Limited Process for the preparation of sevelamer hydrochloride and formulation thereof
CN101687961B (en) * 2007-07-11 2011-10-05 东丽株式会社 Crosslinked polyallylamine or acid addition salt thereof, and use thereof for medical purposes
JP5332520B2 (en) 2007-11-07 2013-11-06 アステラス製薬株式会社 Pharmaceutical tablets
PA8807201A1 (en) * 2007-12-14 2009-07-23 Genzyme Corp PHARMACEUTICAL COMPOSITIONS
EP2361171A4 (en) * 2008-09-15 2014-11-05 Shasun Chemicals And Drugs Ltd Non-aqueous solution process for the preparation of cross-linked polymers
US20100330175A1 (en) * 2009-06-24 2010-12-30 Jobdevairakkam Christopher N Cross-linked polyallylamine tablet core
EP2539380B1 (en) 2010-02-24 2015-08-19 Relypsa, Inc. Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants
CA3023264A1 (en) * 2016-05-06 2017-11-09 Tricida, Inc. Compositions for and method of treating acid-base disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0143328A2 (en) * 1983-10-25 1985-06-05 Nitto Boseki Co., Ltd. Small-flobular crosslinked monoallylamine polymer and process for producing the same
US20050147580A1 (en) * 2003-11-03 2005-07-07 Eric Connor Anion-binding polymers and uses thereof
EP2481414A1 (en) * 2011-02-01 2012-08-01 Chemi SPA A process for the preparation of cross-linked polyallylamines or pharmaceutically acceptable salts thereof
EP3564292A1 (en) * 2016-12-28 2019-11-06 Fujifilm Corporation Emulsion of nitrogen atom-containing polymer or salt thereof, production method therefor, and production method for particles

Also Published As

Publication number Publication date
TW201922268A (en) 2019-06-16
US20210121499A1 (en) 2021-04-29
JP2022027845A (en) 2022-02-14
CA3079171C (en) 2023-09-12
AU2018352766A1 (en) 2020-05-07
US20190321393A1 (en) 2019-10-24
CA3079171A1 (en) 2019-04-25
AU2018352766B2 (en) 2021-09-23
JPWO2019078198A1 (en) 2021-01-07
JP7018451B2 (en) 2022-02-10
EP3698798A1 (en) 2020-08-26
WO2019078198A1 (en) 2019-04-25
CN111246857A (en) 2020-06-05

Similar Documents

Publication Publication Date Title
EP3495400A4 (en) Block copolymer and surface treatment agent using same
EP3622407A4 (en) Patient treatment systems and methods
EP3197518A4 (en) Medicament preparation and treatment devices, methods, and systems
EP3698798A4 (en) Hyperphosphatemia treatment agent, and particles
EP3258883A4 (en) Devices, systems and methods for cardiac treatment
EP3134038A4 (en) Spinal treatment devices, methods, and systems
EP3551238A4 (en) Deodorizing compositions, ostomy devices, and uses thereof
EP3675802A4 (en) Compositions and medical devices comprising anti-microbial particles
EP3409744A4 (en) Surface treatment agent
EP3408344A4 (en) Well treatment methods and compositions
EP3564335A4 (en) Surface treatment agent
EP3558162A4 (en) Obesity treatment devices, systems, and methods
EP3307329A4 (en) Cancer treatment and diagnosis
EP3538189A4 (en) Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
EP3715399A4 (en) Fluoropolyether-group-containing polymer, surface treatment agent, and article
EP3296326A4 (en) Flat elliptical polymer particles, and use thereof
EP3431517A4 (en) Copolymer, and surface treatment agent
EP3525703A4 (en) Treatment devices and methods
EP3431566A4 (en) Surface treatment agent
EP3357934B8 (en) Polymer particles and use thereof
IL271728A (en) Agents, uses and methods for treatment
EP3476382A4 (en) Agent for treating powder for cosmetic, powder for cosmetic, and cosmetic formulated using said powder
EP3719199A4 (en) Paper treatment agent
EP3413906A4 (en) Cancer treatment combination compositions, methods and uses
EP3688023A4 (en) Methods and compositions for cancer treatment

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200416

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: YOSHIDA, HAYATO

Inventor name: TOKUOKA, SHINSUKE

Inventor name: KONDO, YUICHIRO

A4 Supplementary search report drawn up and despatched

Effective date: 20201123

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/785 20060101AFI20201117BHEP

Ipc: A61K 9/24 20060101ALI20201117BHEP

Ipc: A61K 47/38 20060101ALI20201117BHEP

Ipc: A61K 9/32 20060101ALI20201117BHEP

Ipc: A61P 13/12 20060101ALI20201117BHEP

Ipc: A61K 9/16 20060101ALI20201117BHEP

Ipc: A61K 47/26 20060101ALI20201117BHEP

Ipc: A61P 3/00 20060101ALI20201117BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FUJIFILM CORPORATION

Owner name: KYOWA KIRIN CO., LTD.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230120

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240402

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 7/08 20060101ALI20240315BHEP

Ipc: A61K 9/16 20060101ALI20240315BHEP

Ipc: A61K 47/26 20060101ALI20240315BHEP

Ipc: A61K 47/38 20060101ALI20240315BHEP

Ipc: A61P 3/00 20060101ALI20240315BHEP

Ipc: A61P 13/12 20060101ALI20240315BHEP

Ipc: A61K 31/785 20060101AFI20240315BHEP